TG Therapeutics (TGTX) Upgraded to Hold at ValuEngine

ValuEngine upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a report issued on Friday.

A number of other analysts also recently issued reports on the stock. BidaskClub raised shares of TG Therapeutics from a sell rating to a hold rating in a report on Tuesday. B. Riley reissued a buy rating and set a $21.50 price target on shares of TG Therapeutics in a report on Wednesday, January 17th. HC Wainwright reissued a buy rating and set a $33.00 price target on shares of TG Therapeutics in a report on Tuesday, January 16th. Zacks Investment Research downgraded shares of TG Therapeutics from a hold rating to a sell rating in a report on Saturday, January 13th. Finally, Raymond James Financial reissued a buy rating on shares of TG Therapeutics in a report on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. TG Therapeutics currently has a consensus rating of Buy and a consensus price target of $25.50.

Shares of TG Therapeutics (NASDAQ TGTX) traded up $0.50 during midday trading on Friday, reaching $11.80. 2,618,958 shares of the company were exchanged, compared to its average volume of 1,420,000. TG Therapeutics has a 12-month low of $4.50 and a 12-month high of $15.35. The stock has a market capitalization of $870.59, a P/E ratio of -6.11 and a beta of 1.67.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. analysts forecast that TG Therapeutics will post -1.87 EPS for the current year.

In other TG Therapeutics news, CFO Sean A. Power sold 32,006 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 16.70% of the company’s stock.

Large investors have recently bought and sold shares of the business. Legal & General Group Plc raised its position in TG Therapeutics by 14.9% during the second quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 1,463 shares during the period. Voya Investment Management LLC raised its position in TG Therapeutics by 40.2% during the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 6,463 shares during the period. Nationwide Fund Advisors raised its position in TG Therapeutics by 24.2% during the second quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock worth $267,000 after acquiring an additional 5,167 shares during the period. CIBC World Markets Inc. acquired a new position in TG Therapeutics during the fourth quarter worth $250,000. Finally, The Manufacturers Life Insurance Company raised its position in TG Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 36,754 shares of the biopharmaceutical company’s stock worth $370,000 after acquiring an additional 7,630 shares during the period. Institutional investors own 50.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.com-unik.info/2018/02/03/tg-therapeutics-tgtx-upgraded-to-hold-at-valuengine.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit